First-in-class programs keep crossing into clinic
The week’s signal is not a single breakthrough but a steady transfer of promise into human testing: 21,200 active cure-related trials are now in motion, while 11 new cure research items landed in the last 24 hours. Among them, RiboX cleared the FDA for RXIM002, a first-in-class circular RNA-based in vivo CAR therapy for autoimmune cytopenias, and Neurocrine began a Phase 1 study of NBIP-1968, a triple agonist. Stanford’s AI-designed bacteriophage work adds a second, quieter frontier, showing that machine-generated biology can produce something that kills E. coli in the lab. The pattern is clear: the center of gravity is shifting from concept to execution, but every one of these programs still has to survive the long, expensive test of humans. The window is still open.
RiboX Therapeutics received FDA IND clearance for RXIM002, a circular RNA-based in vivo CAR therapy for autoimmune cytopenias, while Neurocrine initiated a Phase 1 study of NBIP-1968 and Stanford researchers reported an AI-designed bacteriophage that killed E. coli in the lab.
If these programs hold, patients with autoimmune disease, metabolic disease, and antibiotic-resistant infection could gain entirely new therapeutic options, while failures would remind the market that translation remains the bottleneck.
Watch for first-in-human readouts, Phase 1 safety signals, and whether AI-designed biology keeps proving it can move beyond design into durable therapeutic effect.